VALUING THE IMPACT OF SYNERGIES ON PUBLIC MERGERS/ACQUSITIONS IN THE PHARMACEUTICAL SECTOR ON THE EUROPEAN CAPITAL MARKETS by Oana Resceanu
 
VALUING THE IMPACT OF SYNERGIES ON PUBLIC MERGERS/ACQUSITIONS IN THE 
PHARMACEUTICAL SECTOR ON THE EUROPEAN CAPITAL MARKETS 
 
Oana Resceanu Ph. D Student 
Academy of Economic Studies  
FABBV 
Bucharest, Romania  
Abstract: : Valuing and identifying synergies in mergers and acquisitions is 
one of the important issues in Corporate Finance. The aim of this paper is to 
value  the  impact  of  synergies  resulted  from  mergers/acquisitions  in  the 
European  pharmaceutical  sector,  realized  between  2004  and  2007.  In  the 
study it has been analyzed the impact of the announcement of the deal on the 
stock price evolution of the acquiring companies for which it was used the 
event  study  technique.  The  results  show  clearly  the  positive  market 
expectations in the day of the announcement as well as 6 days after, however 
the  expected  positive  impact  begins  to  fade  out  resulting  in  negative 
expectations in days 23 and 38, while regaining its confidence in day 39.  
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1. INTRODUCTION  
One important point of interest has always been represented by the reasons why 
mergers occur. The economic theory has provided several possible reasons among which 
attempts  to  create  market  power,  better  corporate  governance,  opportunities  of 
diversification, efficiency related reasons which often involve economy of scales or other 
types of synergies. 
Most of the researches tried to come out with theories in order to explain the 
mergers  and  acquisitions  over  the  last  decades,  and  the  drivers  of  these  mergers  and 
acquisitions.  The  studies  have  been  performed  in  function  of  the  analyzed  period  and 
several main reasons have been identified:  regulatory changes such as antitrust legislations 
or  later  on  deregulation  of  the  markets;  industrial  and  technological  shocks,  or  even 
managerial behavior etc. 
There is one aspect which remains as a central reason for all mergers/acquisitions 
and that is the expected combined effect of the two companies involved in the acquisition 
process which should result into a new entity which should provide synergistic gain and 
should match market expectations. 
Finance literature gives an important role to synergies being also considered as a 
sensible subject. There are several authores who have made important research studies  on 
the synergistic expectaipons and tried to value the impact of these synrgies. Among them 
we have as a promoter  back in 1959 Penrose who saw in  the synergistic hypothesis the 
growth basis for a company fundamentals.   The subject was further developed by Sirower 
(1997) who saw synergies as an increase in competitivity;  Bhide (1993)for whom the 
operating synergy was the primary motive in mergers and acqusitions based on a study of 
77 acqusitions , the results being positive for a third of these companies. 
A  more  recent  approach  is  that  of    Aswarth  Damodaran  (2005)  who  tried  to 
establish through an empirical study how much value do synergies produce and the price for  these  synergies.  His  conclusion  is  not  as  encouraging  as  its  predecessors,  because 
although synergies are expected, only in a few cases they are delivered, or they can cover 
the price paid for the acquired company.   
2. OBJECTIVES  
Reviewing the evidence, it is clear that markets think that there is potential for 
synergy at the time of mergers and acqusitions  but it is also obvious that only a small 
proportion  of  mergers  deliver  considerable  synergy.  In  this  paper  I  study  the  markets 
reaction  and  expectation  of  the  synergistic  gain.  Empirical  researches  on  mergers  and 
acquisitions  over  the  last  century  have  proven  that  in  many  cases  the  effect  of  these 
operations is that of additional value and wealth increase for both target and acquiring 
company.  This  research  paper  is  trying  to  evaluate  if  after  a  merger/acquisition 
announcement there are positive expetaions of synergistic gain for the acquiring company 
and I look to  provide additional evidence to support this, by an up-dated study based on a 
recent sample of public deals between 2004 and 2007. These deals are all public and all 
acquiring companies are listed on European stock exhanges part of EU. 
3. METHODOLOGY  
In this paper are analyzed the market reactions to the acquisition announcement 
and in order to achieve our purpose we used the event study technique to analyze the effect 
of acquisitions and merger announcements of companies in the pharmaceutical sectors 
listed on the European capital markets. 
The study is based on a sample of 45 successful tender offers occurring over the 
period 2004-2007.   The primary data base consisted of 137 public operations (available on 
www.mergermarket.com),  all  of  them  being  European  pharmaceutical  companies 
acquisitions/mergers  within  the  before  mentioned  period.  I  have  to  underline  that  the 
hostile takeovers have been excluded from the initial data . The final sample was reduced 
to only 45 companies due to the fact that in many cases although the offer was public, it 
involved the acquring company being listed and delisted afterwards, thus being difficult to 
conclude with the research.  In other cases I noted several multiple successive acquisitions 
which  made  impossible  a  clear  differentiation  of  one  particular  acquisition  synergistic 
impact. The historical data was no longer available for some of the companies within the 
initial sample because meanwhile they have become a target for someone else, and these 
companies have been excluded. Also all companies which were subsidiaries of other non-
European  companies  (eg: several  Indian  companies have  been  active  on  the European 
pharma market during that period) have been excluded from the final sample. 
The  main  markets  where  these  companies  were  traded  are  London  Stock 
Exchange, Deutsche Borse AG, Nordic Stock Exchange, Borsa Italiana, Vienner Borse and 
as a exception for one UK based company, namely Astra Zeneca have been used data from 
New York Stock Exchange. 
Another important part of the sample is represented by the market index, which 
implied  a  correlation  between  each  company  and  a  significant  index  (I  have  tried  to 
identify  for  all  companies  the  index  they  were  part  of)  Please  see  in  Appendix  1  an 
attached table with all the companies. For each announcement, there have been determined 
the  exact  issuing  date.  In  all  cases,  the  date  of  the  event,  which  appears  as  the 
announcement date in Appendix 1, was considered the date of approval. The abnormal 
return was daily measured during the window event, (T1 + 1, T2], which is composed of 
twenty days before the event, the date of the event, and  60 days after the event. Abnormal  
return has been determined as the difference between the actual return and the normal 
return. To calculate the normal return it is used the market model, a model which relates 
the return of any given stock with the return of the market portfolio. For any security i the 
market model is: 
                
E(εit = 0)         var(εit) = σ2εi 
where Rit and Rmt are the returns of the t period on the security i and the market 
portfolio while εit is the zero mean disturbance term. αi, βi and σ
2
εi are the market model 
parameters. The benefits resulting from the use of market model will depend on the R
2 of 
the market model regression. Unfortunately the regression models made in this study  for 
some of the companies had levels of the before mentioned coefficient quite low, however 
acceptable. We have noted an improvement of the regressions once the right index was 
identified and thus the stock price correlated with the market evolution. 
The  used  estimation  period,  (T0,  T1],  where  t  got  values  for  determining  the 
parameters of the model market, is made up of 230 working days before the event window. 
In the analysis done I took as approximation for the market portfolio several  index (as 
mentioned before) corelated with each company: e.g. Bel 20, FTSE, FTAS, FTSEMIB, 
DAX, MDAX, ATX, Euronext 100, Index Next 150, Cac Mid 100. The used prices of 
shares were the ones at closing. 
By eliminating that part of the return which is due to the variation of the market 
return, the variance of the abnormal return is reduced; this causes an increased ability to 
detect the effects of events. 
If  , t = T1 + 1, ..., T2,is the sample of L2 abnormal returns for the company i in 
the window event, then: 
                 
The abnormal return is the disturbance term of the market model calculated on an 
out  of  the  sample  basis.  Under  the  null  hypothesis  H0  the  distribution  of  the  sample 
abnormal return for a given observation in the event window is: 
˜ N(0, σ2( ))                          
To determine if the announcement had an impact at the level of every day of the 
event window, we conducted the t-test that has supposed the calculation of θ1statistics 
according to the formula: 
                                     
where:  
s = sample standard error of abnormal return during the analyzed day  
n = number of announcements in the sample  
4. ANALYSES 
The  t  test  completion  with  all  the  45  announcements  included  in  the  studied 
sample for each of the 81 days of the event window, led to the determination of 6 days (1 
day before the event and the rest after that date) where the null hypothesis H0 stating that 
the information had no impact is strongly rejected. Adjusting the price of shares to reflect 
the new public information on  mergers and acqusitions is carried out and as expected has 
a positive impact in the day of the announcement and continues to have a positive behavior  
6 days latter implying still a synergistic expectation from the market. If the positive impact 
in the announcemnt day can be argued by some as being also influenced by the control 
premiums the evolution in day 6 can be only the result of expected synergies. Although the markets expectaions seem to drop in days 23 and 38, we can see that the final impact is a 
positive one as the market still expects a positive outcome. 








Note: the level of significance is 5%. 
This study confirms the results of previous empirical research on the expected of 
the expected synergies in the short term. However it becomes very difficult to demonstrate 
this on the longer term.  
5. CONCLUSIONS  
Due to an unprecedented wave of mergers and acquisitions which has transformed 
the entire industry (including the pharmaceutical subsector) plus value has been created, 
however there are also a relatively large number of failures which show that the theory is 
not always applicable in practice. Moreover almost everyone associates the concept of 
synergy  with  the  theory  of  efficiency,  which  supports  the  creation  of  value  through 
mergers/acquisitions.  
The study showed that on a short period of time can be identified positive market 
reactions to the announced mergers and acquisitions based on the expected synergistic 
impact. Many  argue that it is difficult to identify the sources of positive gain in mergers 
and acquisitions, but after reviewing the results, it is clear that markets think that there is 
potential gain for synergy at the time of mergers. The expectaions are not always positively 
correlated  with  the  actual  resulted    synergy  from  mergers/acqusitions  and  positive  or 
negative synergy can exist, the condition being that when the companys parts interact to 
produce a joint effect it should be greater than the sum of the parts acting alone. 
This study shows a similar behavior of markets for the selected sample and as a 
next step it will be enlarged including also the crisis period in order to see if the crisis  has 
inflicted a diffrent behavior to the markets expectations for synergy. A second direction 
would be to analyze the behavior and synergistic expectations for Romanian companies 
involved in a merger/acquisition process. 
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announcement Symbol Purchaser Target Value Type of acqusition
1 Deutschland 12/20/2004 CLS1 Celesio AG Healthcare Logistics LTD 82 Acquisition, Cross border, Private
2 Deutschland 12/22/2004 SAZ.F Stada Arzneimittel AG Nizhpharm JSC 81 Acquisition, Cross border, Private
3 Italy 1/17/2005 REC.MI Recordati Spa Merckle Gmbh 45 Acquisition, Cross border, Private
4 UK 3/4/2005 BII
Biocompatibles 
International PLC CellMed AG 10 Acquisition, Cross border, Private
5 France 3/4/2005 BOI.PA Boiron SA Dolisos 10 Acquisition, Domestic, Private
6 Deutschland 3/6/2005 EVTA.F Evotec AG
Evotec Neurosciences 
GMBH 37 Acquisition, Domestic, Private
7 Deutschland 4/11/2005 SAZ.F Stada Arzneimittel AG Ciclum farma 31 Acquisition, Cross border, Private
8 Sweden 6/27/2005 BIOP BioPaushia AB Cross Pharma Group AB 4 Acquisition, Domestic, Public
9 UK 7/6/2005 VER Vernalis PLC
Ionix Pharmaceuticals 
Limited 18 Acquisition, Domestic, Private
10 Belgium 7/12/2005 SVYSY Solvay SA Fournier Pharma 1200 Acquisition, Cross border, Private
11 Sweden 8/8/2005 MDABF.PK Meda AB Meda Pharma GMBH 750 Acquisition, Cross border, Private
12 Sweden 8/22/2005 BVT Biovitrum AB Arexis AB 13 Acquisition, Cross border, Private
13 Spain 9/14/2005 MRK.F
Merck Genericos 
(subsidiara companiei 
germane)  Prasfarma SA 20 Acquisition, Cross border, Private
14 Czech Republic 9/15/2005 UWW.SG Zentiva NV Venoma Holdings Limited 83 Acquisition, Cross border, Public
15 Belgium 9/21/2005 GLPG.BR Galapagos NV BioFocus DPI 28 Acquisition, Cross border, Public
16 Deutschland 10/14/2005 CLS1
Lloydspharmacy Limited 
(Celesio AG)
111 Cohens and Scholes 
Pharmacies 146 Acquisition, Cross border, Private
17 Deutschland 11/18/2005 MRK.F Merck KGaA Survac ApS 11 Acquisition, Cross border, Private
18 UK 12/23/2005 AZN Astra Zeneca PLC
Kudos Pharmaceuticals 
limited 177 Acquisition, Cross border, Private
19 UK 3/13/2006 SPH.L Sinclair Pharma PLC
Groupe CS Dermatologie 
SAS 53 Acquisition, Cross border, Private
20 Deutschland 3/24/2006 Baya.F Bayer AG
Bayer Schering Pharma 
AG 15637 Acquisition, Domestic, Public
21 France 3/27/2006 SAN.PA Sanofi Aventis Zentiva NV 430 Acquisition, Cross border, Private
22 UK 5/15/2006 AZN Astra Zeneca PLC
Cambridge Antibody 
Technology Group Plc 810 Acquisition, Domestic, Public
23 Belgium 6/13/2006 GLPG.BR Galapagos NV
Discovery Parteners 
International  4 Acquisition, Cross border, Private
24 Italy 7/28/2006 REC.MI Recordati Spa Jaba Farmaceutica 45 Acquisition, Cross border, Private
25 Denmark 8/23/2006 NeuroSearch NeuroSearch AS Carlsson Research AB 27 Acquisition, Cross border, Private
26 Deutschland 8/30/2006 MDG.F Medigene AG Avidex Limited 48 Acquisition, Domestic, Private
27 Deutschland 11/8/2006 Baya.F Bayer AG
Bayer Schering Pharma 
AG 1112 Acquisition, Cross border, Public
28 Sweden 11/9/2006 MDABF.PK Meda AB 3M Company 668 Acquisition, Cross border, Public
29 UK 11/17/2006 Vec.L Vectura Group Innovata Plc 161 Acquisition, Domestic, Public
UK 12/8/2006 GLAXO.NS GSK Domantis 347 Acquisition, Cross border, Private
UK 12/19/2006 GLAXO.NS GSK Genmab A/S 273 Acquisition, Cross border, Public
30 Hungary 12/19/2006 RIG1.F
Armedica Trading 
(Gedeon Richter) Dita Group 15 Acquisition, Cross border, Private
32 Austria 1/15/2007 IJE.F Intercell AG Pelias Biomedizinische 6 Acquisition, Domestic, Private
33 UK 1/22/2007 HIK Hikma Pharmaceuticals Ribosepharm Gmbh 35 Acquisition, Cross border, Private
34 UK 1/24/2007 NUT.L NeutraHealth Brunel Healthcare Limited 10 Acquisition, Domestic, Private
35 UK 2/1/2007 AZN Astra Zeneca PLC Arrow Therapeutics 115 Acquisition, Domestic, Private
36 France 3/1/2007 BCG.L BTG Industries et Sante Vita Pharma AS 25 Acquisition, Cross border, Private
37 UK 3/12/2007 Oxb Oxford Biomedica
Oxxon Therapeutics 
Limited 19 Acquisition, Cross border, Private
38 Denmark 4/11/2007 Topo Topo Target AS Apoxis SA 15 Acquisition, Cross border, Private
39 UK 4/12/2007 FUL.L Fulcrum Pharma Plc
Unicus Regulatory 
Services limited 7 Acquisition, Domestic, Private
40 Hungary 8/6/2007 RIG1.F Gedeon Richter Strathmann Biotec 23 Acquisition, Cross border, Private
41 Deutschland 8/31/2007 SAZ.F Stada Arzneimittel AG
Forum Biosciences 
Holdings Ltd 47 Acquisition, Cross border, Private
42 Italy 9/28/2007 REC.MI Recordati Spa Orphan Europe 135 Acquisition, Cross border, Private
43 Sweden 10/15/2007 ORX.ST Orexo AB Biolipox AB 77 Acquisition, Cross border, Public
44 Sweden 10/25/2007 MDABF.PK Meda AB Recip AB 343 Acquisition, Domestic, Public
45 UK 12/12/2007 DPH.L Dechra VetXX A/S 86 Acquisition, Cross border, Public
31
 APPENDIX 2 
Day Rentability
Cumulated 
Rentability AR CAR Standard error θ1
60 0.06% 3.82% 0.71% -1.52% 0.0047 1.5222
59 0.16% 3.77% -0.34% -2.24% 0.0055 -0.6246
58 -0.12% 3.60% -0.42% -1.89% 0.0044 -0.9555
57 0.12% 3.73% 0.00% -1.47% 0.0037 -0.0008
56 -0.11% 3.61% 0.25% -1.47% 0.0039 0.6463
55 0.06% 3.72% -0.02% -1.73% 0.0032 -0.0596
54 0.05% 3.66% -0.35% -1.71% 0.0045 -0.7755
53 0.00% 3.61% -0.28% -1.36% 0.0031 -0.9018
52 0.05% 3.61% 0.13% -1.08% 0.0025 0.5029
51 -0.02% 3.56% -0.33% -1.20% 0.0031 -1.0516
50 -0.07% 3.58% 0.73% -0.88% 0.0039 1.9009
49 0.08% 3.65% -0.32% -1.61% 0.0048 -0.6552
48 0.20% 3.56% 0.11% -1.29% 0.0043 0.2509
47 -0.18% 3.37% 0.29% -1.40% 0.0057 0.5112
46 -0.21% 3.55% -0.10% -1.69% 0.0042 -0.2508
45 0.29% 3.76% -0.24% -1.59% 0.0038 -0.6362
44 0.27% 3.46% 0.21% -1.34% 0.0026 0.8051
43 0.07% 3.20% 0.37% -1.55% 0.0035 1.0776
42 -0.11% 3.12% -0.61% -1.93% 0.0035 -1.7269
41 0.14% 3.24% 0.16% -1.32% 0.0028 0.5854
40 -0.16% 3.10% -0.05% -1.48% 0.0029 -0.1688
39 0.27% 3.26% 0.76% -1.43% 0.0033 2.2924
38 -0.08% 2.99% -0.77% -2.19% 0.0035 -2.2210
37 0.10% 3.07% -0.11% -1.41% 0.0030 -0.3752
36 0.10% 2.97% 0.07% -1.30% 0.0028 0.2397
35 0.04% 2.87% -0.70% -1.37% 0.0037 -1.8954
34 -0.09% 2.82% 0.11% -0.67% 0.0027 0.4025
33 0.11% 2.92% -0.39% -0.78% 0.0031 -1.2667
32 0.25% 2.80% 0.43% -0.39% 0.0037 1.1464
31 -0.24% 2.56% -0.10% -0.81% 0.0033 -0.3185
30 0.10% 2.80% 0.63% -0.71% 0.0037 1.7082
29 0.07% 2.70% -0.06% -1.34% 0.0034 -0.1772
28 0.18% 2.63% -0.08% -1.28% 0.0032 -0.2576
27 0.06% 2.45% -0.72% -1.19% 0.0044 -1.6252
26 0.01% 2.39% 0.03% -0.48% 0.0039 0.0782
25 0.00% 2.38% 0.06% -0.51% 0.0029 0.2116
24 -0.16% 2.37% 0.45% -0.57% 0.0037 1.2055
23 0.05% 2.54% -0.81% -1.01% 0.0039 -2.0489
22 0.25% 2.49% -0.25% -0.21% 0.0044 -0.5623
21 -0.11% 2.24% -0.27% 0.04% 0.0033 -0.8084
20 -0.11% 2.34% 0.27% 0.31% 0.0028 0.9981
19 0.10% 2.45% -0.36% 0.04% 0.0032 -1.1260
18 -0.01% 2.35% 0.46% 0.40% 0.0032 1.4354
17 -0.12% 2.37% -0.39% -0.06% 0.0044 -0.8744
16 0.04% 2.48% 0.02% 0.32% 0.0034 0.0727
15 0.09% 2.44% 0.09% 0.30% 0.0029 0.2913
14 0.05% 2.35% 0.12% 0.21% 0.0036 0.3431
13 0.13% 2.30% -0.54% 0.09% 0.0028 -1.9180
12 0.06% 2.17% -0.23% 0.63% 0.0031 -0.7360
11 -0.03% 2.11% -0.23% 0.86% 0.0028 -0.8323
10 0.14% 2.14% -0.28% 1.09% 0.0039 -0.7151
9 -0.15% 2.00% 0.05% 1.37% 0.0023 0.1948
8 -0.02% 2.15% -0.37% 1.32% 0.0029 -1.2815
7 0.23% 2.17% 0.22% 1.69% 0.0033 0.6571
6 -0.05% 1.93% 0.78% 1.48% 0.0038 2.0210
5 0.00% 1.98% -0.47% 0.70% 0.0027 -1.7496
4 0.02% 1.98% -0.40% 1.17% 0.0024 -1.6885
3 -0.08% 1.96% 0.18% 1.58% 0.0030 0.5982
2 0.16% 2.04% -0.08% 1.40% 0.0047 -0.1604
1 0.12% 1.88% 0.59% 1.47% 0.0064 0.9290
0 -0.10% 1.76% 1.68% 0.88% 0.0082 2.0360
-1 0.06% 1.86% -0.49% -0.80% 0.0035 -1.4043
-2 0.28% 1.80% 0.03% -0.30% 0.0026 0.1031
-3 -0.01% 1.51% 0.61% -0.33% 0.0039 1.5581
-4 0.02% 1.53% 0.80% -0.94% 0.0035 2.2667
-5 0.14% 1.50% 0.44% -1.74% 0.0043 1.0191
-6 0.11% 1.36% -0.38% -2.18% 0.0029 -1.3313
-7 0.05% 1.25% -0.34% -1.79% 0.0023 -1.4876
-8 0.05% 1.20% -0.26% -1.45% 0.0026 -1.0211
-9 0.14% 1.15% -0.29% -1.19% 0.0025 -1.1602
-10 0.18% 1.02% 0.16% -0.89% 0.0020 0.8034
-11 0.05% 0.84% 0.10% -1.05% 0.0028 0.3504
-12 0.18% 0.79% -0.10% -1.15% 0.0023 -0.4153
-13 0.01% 0.60% -0.10% -1.06% 0.0025 -0.4210
-14 0.34% 0.60% -0.07% -0.95% 0.0039 -0.1844
-15 0.09% 0.26% -0.22% -0.88% 0.0025 -0.8688
-16 -0.13% 0.17% -0.43% -0.66% 0.0025 -1.7087
-17 -0.04% 0.30% 0.09% -0.23% 0.0035 0.2716
-18 0.14% 0.34% -0.18% -0.33% 0.0036 -0.5043
-19 -0.11% 0.20% -0.34% -0.15% 0.0025 -1.3614
-20 0.32% 0.32% 0.19% 0.19% 0.0030 0.6365  